55 related articles for article (PubMed ID: 30298208)
1. Effect of Tacrolimus Formulation (Prolonged-Release vs Immediate-Release) on Its Susceptibility to Drug-Drug Interactions with St. John's Wort.
Gümüs KS; Teegelbekkers A; Sauter M; Meid AD; Burhenne J; Weiss J; Blank A; Haefeli WE; Czock D
Clin Pharmacol Drug Dev; 2024 Mar; 13(3):297-306. PubMed ID: 38176912
[TBL] [Abstract][Full Text] [Related]
2. PBTK model-based analysis of CYP3A4 induction and the toxicokinetics of the pyrrolizidine alkaloid retrorsine in man.
Lehmann A; Geburek I; Hessel-Pras S; Enge AM; Mielke H; Müller-Graf C; Kloft C; Hethey C
Arch Toxicol; 2024 Jun; 98(6):1757-1769. PubMed ID: 38528153
[TBL] [Abstract][Full Text] [Related]
3. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.
Lown KS; Bailey DG; Fontana RJ; Janardan SK; Adair CH; Fortlage LA; Brown MB; Guo W; Watkins PB
J Clin Invest; 1997 May; 99(10):2545-53. PubMed ID: 9153299
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017.
Maliepaard M; Toiviainen T; De Bruin ML; Meulendijks D
Clin Pharmacol Ther; 2020 Aug; 108(2):338-349. PubMed ID: 32236952
[TBL] [Abstract][Full Text] [Related]
5. An Uncertainty-Guided Deep Learning Method Facilitates Rapid Screening of CYP3A4 Inhibitors.
Wang R; Liu Z; Gong J; Zhou Q; Guan X; Ge G
J Chem Inf Model; 2023 Dec; 63(24):7699-7710. PubMed ID: 38055780
[TBL] [Abstract][Full Text] [Related]
6. Assessing Toxicokinetic Uncertainty and Variability in Risk Prioritization.
Wambaugh JF; Wetmore BA; Ring CL; Nicolas CI; Pearce RG; Honda GS; Dinallo R; Angus D; Gilbert J; Sierra T; Badrinarayanan A; Snodgrass B; Brockman A; Strock C; Setzer RW; Thomas RS
Toxicol Sci; 2019 Dec; 172(2):235-251. PubMed ID: 31532498
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the Effects of Acute Inflammation on Pharmacokinetics: A Model-Based Analysis Focusing on Renal Glomerular Filtration Rate and Cytochrome P450 3A4-Mediated Metabolism.
Liu F; Aulin LBS; Manson ML; Krekels EHJ; van Hasselt JGC
Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):623-631. PubMed ID: 37715056
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological, Physiochemical, and Drug-Relevant Biological Properties of Short Chain Fatty Acid Hexosamine Analogues Used in Metabolic Glycoengineering.
Saeui CT; Liu L; Urias E; Morrissette-McAlmon J; Bhattacharya R; Yarema KJ
Mol Pharm; 2018 Mar; 15(3):705-720. PubMed ID: 28853901
[TBL] [Abstract][Full Text] [Related]
9. Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics.
Wambaugh JF; Hughes MF; Ring CL; MacMillan DK; Ford J; Fennell TR; Black SR; Snyder RW; Sipes NS; Wetmore BA; Westerhout J; Setzer RW; Pearce RG; Simmons JE; Thomas RS
Toxicol Sci; 2018 May; 163(1):152-169. PubMed ID: 29385628
[TBL] [Abstract][Full Text] [Related]
10. Prediction of the Contribution Ratio of a Target Metabolic Enzyme to Clearance from Chemical Structure Information.
Watanabe R; Kawata T; Ueda S; Shinbo T; Higashimori M; Natsume-Kitatani Y; Mizuguchi K
Mol Pharm; 2023 Jan; 20(1):419-426. PubMed ID: 36538346
[TBL] [Abstract][Full Text] [Related]
11. Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis.
Damoiseaux D; Schinkel AH; Beijnen JH; Huitema ADR; Dorlo TPC
Clin Transl Sci; 2024 Jan; 17(1):e13668. PubMed ID: 38037826
[TBL] [Abstract][Full Text] [Related]
12. CYP3A4/P-glycoprotein inhibitors related colchicine toxicity mimicking septic shock.
Ngeyvijit J; Nuansuwan S; Phoophiboon V
BMJ Case Rep; 2023 Oct; 16(10):. PubMed ID: 37813551
[TBL] [Abstract][Full Text] [Related]
13. Predictive Models for Human Cytochrome P450 3A7 Selective Inhibitors and Substrates.
Xu T; Kabir M; Sakamuru S; Shah P; Padilha EC; Ngan DK; Xia M; Xu X; Simeonov A; Huang R
J Chem Inf Model; 2023 Feb; 63(3):846-855. PubMed ID: 36719788
[TBL] [Abstract][Full Text] [Related]
14. Invited Perspective: Uneven Progress Addressing Population Variability in Human Health Risk Assessment.
Chiu WA
Environ Health Perspect; 2024 Mar; 132(3):31305. PubMed ID: 38498339
[No Abstract] [Full Text] [Related]
15. Risk Assessment of Combined Exposure to Multiple Chemicals at the European Food Safety Authority: Principles, Guidance Documents, Applications and Future Challenges.
Cattaneo I; Kalian AD; Di Nicola MR; Dujardin B; Levorato S; Mohimont L; Nathanail AV; Carnessechi E; Astuto MC; Tarazona JV; Kass GEN; Liem AKD; Robinson T; Manini P; Hogstrand C; Price PS; Dorne JLCM
Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668860
[TBL] [Abstract][Full Text] [Related]
16. A Population-Based Human In Vitro Approach to Quantify Inter-Individual Variability in Responses to Chemical Mixtures.
Ford LC; Jang S; Chen Z; Zhou YH; Gallins PJ; Wright FA; Chiu WA; Rusyn I
Toxics; 2022 Aug; 10(8):. PubMed ID: 36006120
[TBL] [Abstract][Full Text] [Related]
17. Guidance on harmonised methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals.
; More SJ; Bampidis V; Benford D; Bennekou SH; Bragard C; Halldorsson TI; Hernández-Jerez AF; Koutsoumanis K; Naegeli H; Schlatter JR; Silano V; Nielsen SS; Schrenk D; Turck D; Younes M; Benfenati E; Castle L; Cedergreen N; Hardy A; Laskowski R; Leblanc JC; Kortenkamp A; Ragas A; Posthuma L; Svendsen C; Solecki R; Testai E; Dujardin B; Kass GE; Manini P; Jeddi MZ; Dorne JC; Hogstrand C
EFSA J; 2019 Mar; 17(3):e05634. PubMed ID: 32626259
[TBL] [Abstract][Full Text] [Related]
18. The Yin-Yang of CYP3A4: a Bayesian meta-analysis to quantify inhibition and induction of CYP3A4 metabolism in humans and refine uncertainty factors for mixture risk assessment.
Quignot N; Wiecek W; Amzal B; Dorne JL
Arch Toxicol; 2019 Jan; 93(1):107-119. PubMed ID: 30298208
[TBL] [Abstract][Full Text] [Related]
19. Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.
Quignot N; Więcek W; Lautz L; Dorne JL; Amzal B
Toxicol Lett; 2021 Feb; 337():111-120. PubMed ID: 33232775
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
